Podcast: Play in new window | Download
Subscribe: Apple Podcasts |
Episode 62 Show Notes July 2023
- Comparison of endoscopic sleeve gastroplasty versus surgical sleeve gastrectomy: a database analysis. – GIE
- Incidence and natural history of gastric high grade dysplasia in patients with FAP. – GIE
- Association of Life Expectancy with surveillance colonoscopy findings and follow up recommendations in Older adults – Jama IM
- Physician decision-making about surveillance in older adults with prior adenomas: results from a national study. – Am J Gastro
- Hpylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT) – RCT – Lancet 2022
- Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridiodes difficile Infection – CGH
We often talk to
our patients with cirrhosis regarding the risk of HCC, and putting aside the debate as to the efficacy of screening for such, most of our patients get the ultrasound twice yearly, +/- AFP every so often, and we cross our fingers and hope for the best, given how non-existent effective therapy for HCC is (other than resection).
This article in CGH – which regained the title of my second most favorite GI journal this week, is an article from the Texan folks, discussing HCC in the absence of cirrhosis.
This is a review of the Veteran’s Affairs database (boy would I love to get my hands on that!), 2005-2011 diagnoses of HCC, which was limited to 1500 random charts (obtained from a total of 10,695 HCC diagnoses).
~80% of the patients diagnosed with HCC had cirrhosis. Which means ~20% did not. Who are these remaining folks?
Many had metabolic syndrome, NAFLD, but some had no risk factors whatsoever. It is interesting that in the cohort of 43 patients with what authors defined as “No cirrhosis – very high probability” – many still had some fibrosis.
In any case, logistic regression to look for associations and risk factors for HCC in absence of cirrhosis was conducted. Results:
NAFLD, HCV, HBV, Alcohol abuse, Metabolic syndrome, Others (hemochromatosis, autoimmune hepatitis, A1-AT deficiency). Idiopathic – only in 13 out of 194 patients!
- Glad to know that we are aware of major risk factors for HCC even in the absence of cirrhosis.
- No evidence as of yet to expand the risk pool to screen patients without evidence of cirrhosis.
- If chemoprevention is ever developed, now we know a good population to apply it in ( ex – Maybe Metformin?.
- It would be nice to have a large data dump of such patients on a national level, and include other variables in analysis, such as factors associated with good outcome or poor outcome. I suppose we can wait for the next paper.